Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.
Brief Summary: This study will assess the efficacy, safety and tolerability of QVA149 in patients with moderate to severe airflow limitation.


Options:
A: Arm Label: Aclidinium/Formoterol 400/6 μg; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium Bromide/Formoterol Fumarate | Arm Label: Aclidinium/Formoterol 400/12 μg; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium Bromide/Formoterol Fumarate | Arm Label: Aclidinium monotherapy 400 μg; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium Bromide | Arm Label: Formoterol monotherapy 12 μg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Formoterol Fumarate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aclidinium Bromide/Formoterol Fumarate; Assigned to Arm(s): Aclidinium/Formoterol 400/6 μg | Intervention Type: DRUG; Name: Aclidinium Bromide/Formoterol Fumarate; Assigned to Arm(s): Aclidinium/Formoterol 400/12 μg | Intervention Type: DRUG; Name: Aclidinium Bromide; Assigned to Arm(s): Aclidinium monotherapy 400 μg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Formoterol Fumarate; Assigned to Arm(s): Formoterol monotherapy 12 μg
B: Arm Label: NVA237 + indacaterol; Type: ACTIVE_COMPARATOR; Interventions: Drug: NVA237 50 µg and indacaterol 150 µg | Arm Label: Placebo to NVA237 + indacaterol; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo to NVA237 and indacaterol 150 µg | Intervention Type: DRUG; Name: NVA237 50 µg and indacaterol 150 µg; Assigned to Arm(s): NVA237 + indacaterol | Intervention Type: DRUG; Name: Placebo to NVA237 and indacaterol 150 µg; Assigned to Arm(s): Placebo to NVA237 + indacaterol
C: Arm Label: NVA237; Type: EXPERIMENTAL; Interventions: Drug: NVA237, Drug: Placebo to tiotropium, Drug: salbutamol/albuterol | Arm Label: Tiotropium; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tiotropium, Drug: Placebo to NVA237 | Intervention Type: DRUG; Name: NVA237; Assigned to Arm(s): NVA237 | Intervention Type: DRUG; Name: Tiotropium; Assigned to Arm(s): Tiotropium | Intervention Type: DRUG; Name: Placebo to tiotropium; Assigned to Arm(s): NVA237 | Intervention Type: DRUG; Name: Placebo to NVA237; Assigned to Arm(s): Tiotropium | Intervention Type: DRUG; Name: salbutamol/albuterol; Assigned to Arm(s): NVA237
D: Arm Label: QVA149; Type: EXPERIMENTAL; Interventions: Drug: QVA149 | Arm Label: QAB149; Type: ACTIVE_COMPARATOR; Interventions: Drug: QAB149 | Arm Label: NVA237; Type: ACTIVE_COMPARATOR; Interventions: Drug: NVA237 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: QVA149; Assigned to Arm(s): QVA149 | Intervention Type: DRUG; Name: QAB149; Assigned to Arm(s): QAB149 | Intervention Type: DRUG; Name: NVA237; Assigned to Arm(s): NVA237 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D